Evaluation of the efficacy of potassium iodide preparation for radioactive iodine therapy in Graves' disease
- Conditions
- Graves'disease
- Registration Number
- JPRN-UMIN000024893
- Lead Sponsor
- Yamashita thyroid and parathyroid clinic
- Brief Summary
RAIU before RAIT (p=0.0018), dose of 131-I (p=0.0037), FT4 at RAIT (p=0.0034), and thyroid gland weight one year after RAIT (p=0.0065) showed significant differences. Thyroid gland weight, dose of 131-I based on thyroid gland weight, difference in FT4 between before drug discontinuation and at RAIT, and thyroid function at one year after RAIT did not show any significant differences. These results suggest that most patients without large goiter and/or highly aggressive disease may be safely and efficiently treated with RAIT and KI pretreatment until 4 days before therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 24
Not provided
The exclusion criteria was defined as follows; large goiter and/or experience of previous RAIT. The definition of large goiter in exclusion criteria was determined that estimated thyroid gland weight was more than 50 g.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method variation of FT4 between before and at 4 days after discontinuation of methimazole (MMI) or KI between KI prepariton group and MMI preparation group
- Secondary Outcome Measures
Name Time Method Radioactive iodine uptake before RAIT, thyroid gland weight, dose of administered 131-I, dose of 131-I based on thyroid gland weight, free thyroxine (FT4) at RAIT, thyroid function at one year after RAIT and thyroid gland weight at one year after RAIT between above two gruops